INNOTEST^® ß- AMYLOID_(1-42)

INNOTEST^® ß- AMYLOID(1-42) is an ELISA microplate assay for the quantitative determination of human ß-amyloid1-42(Aß1-42) in human cerebrospinal fluid (CSF).

Combined use of CSF-tau and CSF-Aß1-42 markers allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurologic disorders such as depression (1-5).

Article number: 80324 (96T), 80325 (3V)

The CE-marked kit allows easy, reliable, and specific quantification of CSF-Aß1-42. The combined use of CSF-tau and CSF-Aß1-42 markers allows differentiation between AD and normal aging or other neurologic disorders such as depression.

Disclaimer
A license regarding Amyloid beta antibodies contained in this product under patents US 570349 and EP 0683234 has been obtained from Takeda Pharmaceutical Company Limited.
Furthermore, a license for the use of Amyloid beta monoclonal antibodies contained in this product under patents US 5,593,846A, US 5,766,846A, US 5,837,672A, US 6,284,221B1, US 6,610,493B1, US 5,441,870A, US 5,721,130A, US 5,605,811A and US 6,114,133A has been obtained from Eli Lilly and Company.

Features & Benefits

• User-friendly enzyme immunoassay
  
  
• Minimum number of handling steps
  
  
• Small sample volume: 25 µL CSF. Duplicate testing is strongly recommended and requires
  2 x 25 µL CSF
  
  
• Reproducible results within the standards range
  
  
• Lowest detection limit: 50 pg/mL (5 pg/mL*)
  Standards range: 125 to 2000 pg/mL (7.8 to 1000 pg/mL*)
  *This assay can also be use to measure lower concentrations (eg. In cell culture supernatants) by following high-sensitivity test protocol. However, this protocol has not been validated and is therefore only available for research use only. Contact customer service for more details.

Background

1. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using ß-amyloid1-42 and tau levels in CSF. Neurology 1999;52:1555-1562.
   
2. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid ß42 levels in the clinical diagnosis of Alzheimer’s disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
   
3. Shoji M, Kanai M, Matsubara E, Ikeda M, Harigaya Y, Okamoto K, et al. Taps to Alzheimer’s patients: a continuous Japanese study of cerebrospinal fluid markers. Ann Neurol 2000;48:402.
   
4. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF- Aß42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
   
5. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased b-amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer disease. Journal of the American Medical Association 2003;289:2094-2103.

Additional useful information about Alzheimer’s disease can be found on the following websites: The Alzheimer forum site:
http://www.alzforum.org/new/detail.asp?id=875
http://www.alzforum.org/new/detail.asp?id=804
http://www.alzforum.org/new/detail.asp?id=709